Form D · Biotechnology
Eureka Therapeutics, Inc.
Emeryville, CA · CIK 0001386560
Offering snapshot reported May 17, 2023 · SEC filing
- Reported sold
- Yet to sell Offering amount: $20M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 24, 2020 | Initial | $45,000,000 | No comparison | 20 | SEC filing |
| Jun 18, 2018 | Initial | $20,000,000 | No comparison | 2 | SEC filing |
| May 30, 2017 | Amendment | $26,572,831 | No comparison | 40 | SEC filing |
| Dec 12, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Sep 22, 2014 | Initial | $21,000,000 | No comparison | 28 | SEC filing |
| Nov 4, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 30, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 8, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-481903
Convertible promissoy notes (Notes) that is convertible into Issuer capital stock (Note Stock), and shares of Note Stock into which the Notes may convert.
Source: Form D, filed May 17, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Cannon | Director |
| Vivien Chan | Executive |
| Wai Yan "Sandy" Chau | Director |
| Sandy Chau | Director |
| Chih Kai "C.K." Cheng | Director |
| Chih Kai Cheng | Director |
| Chih Kai "C.K. Cheng | Director |
| Bo Feng | Director |
| Qiushi Fu | Director |
| Reed Jobs | Director |
| Hsing Kung | Director |
| Christopher Lehman | Executive |
| Cheng Liu | Director, Executive |
| Bijan Nejadnik | Executive |
| Jacqueline Northcut | Director |
| Marvin Samson | Director |
| Victor Shum | Executive |
| William S. Solari Iii | Director |
| Wiliam S. Solari Iii | Director |
| Lewis T. Williams | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5858 Horton St Ste 370
Emeryville, CA, 94608
Emeryville, CA, 94608